Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deffered Revenue (2019 - 2022)

Revolution Medicines has reported Non-Current Deffered Revenue over the past 4 years, most recently at $5.4 million for Q3 2022.

  • Quarterly results put Non-Current Deffered Revenue at $5.4 million for Q3 2022, down 44.02% from a year ago — trailing twelve months through Sep 2022 was $5.4 million (down 44.02% YoY), and the annual figure for FY2021 was $6.6 million, down 22.5%.
  • Non-Current Deffered Revenue for Q3 2022 was $5.4 million at Revolution Medicines, up from $3.8 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for RVMD hit a ceiling of $14.7 million in Q4 2019 and a floor of $3.8 million in Q2 2022.
  • Median Non-Current Deffered Revenue over the past 4 years was $8.3 million (2020), compared with a mean of $8.7 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: decreased 0.97% in 2021 and later tumbled 49.65% in 2022.
  • Revolution Medicines' Non-Current Deffered Revenue stood at $14.7 million in 2019, then plummeted by 42.41% to $8.5 million in 2020, then decreased by 22.5% to $6.6 million in 2021, then decreased by 17.57% to $5.4 million in 2022.
  • The last three reported values for Non-Current Deffered Revenue were $5.4 million (Q3 2022), $3.8 million (Q2 2022), and $5.7 million (Q1 2022) per Business Quant data.